Meeting
2023 ASCO Genitourinary Cancers Symposium
Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan.
Authors
Lin Wang
Merck & Co., Inc., Rahway, NJ
Lin Wang , Arielle G. Bensimon , Murali Sundaram , Ruifeng Xu , Yizhen Lai , Yanfang Liu , Shahrul Mt-Isa , Danni Yang , Jonathan Freimark , Yan Song , Eric Jonasch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Other
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 733)
DOI
10.1200/JCO.2023.41.6_suppl.733
Abstract #
733
Poster Bd #
L8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Healthcare resource utilization (HRU) and costs among patients with Von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC): A retrospective administrative claims analysis.
First Author: Eric Jonasch
Poster
2021 Genitourinary Cancers Symposium
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
First Author: Othon Iliopoulos
Poster
2023 ASCO Annual Meeting
Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience.
First Author: Othon Iliopoulos
Poster
2023 ASCO Annual Meeting
Real-world outcomes and safety in patients with VHL associated tumors receiving belzutifan.
First Author: Anusha Chidharla